RAHWAY, N.J.--(BUSINESS WIRE) September 4, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and EyeBio, a...
Vous n'êtes pas connecté
RAHWAY, N.J.--(BUSINESS WIRE) August 27, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of Shorespan-007, a pivotal Phase 3 clinical trial evaluating bomedemstat, an investigational...
RAHWAY, N.J.--(BUSINESS WIRE) September 4, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and EyeBio, a...
BOULDER, Colo.--(BUSINESS WIRE)-- September 05, 2024 -- Crestone, Inc. (“Crestone”) today announced positive topline results from the Phase 2...
BOULDER, Colo.--(BUSINESS WIRE)-- September 05, 2024 -- Crestone, Inc. (“Crestone”) today announced positive topline results from the Phase 2...
BASKING RIDGE, N.J. & RAHWAY, N.J., September 7, 2024 – Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01...
BASKING RIDGE, N.J. & RAHWAY, N.J., September 7, 2024 – Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01...
Pharvaris provides business update and expands development program for deucrictibant Pharvaris today announced: The planned initiation of CHAPTER-3,...
HOUSTON, Sept. 9, 2024. Moleculin Biotech, Inc., ("Moleculin" or the "Company), a Phase 3 clinical-stage pharmaceutical company with a broad portfolio...
The clinical study will evaluate MRK's experimental antibody treatment in patients with diabetic macular edema, a major cause of vision loss.
WEDNESDAY, Sept. 4, 2024 -- An experimental three-in-one blood pressure pill works better than layering on meds one at a time, a new clinical trial...
SOLARIS, a phase 3 clinical trial led by Dana-Farber Cancer Institute, tested the addition of high-dose medlinkvitamin D3/medlink to standard...